Rallybio Corp (RLYB)
1.545
-0.12
(-6.93%)
USD |
NASDAQ |
Jun 14, 16:00
1.55
0.00 (0.00%)
After-Hours: 20:00
Rallybio Enterprise Value: -30.14M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | -30.14M |
| June 13, 2024 | -25.37M |
| June 12, 2024 | -25.78M |
| June 11, 2024 | -26.20M |
| June 10, 2024 | -30.96M |
| June 07, 2024 | -32.83M |
| June 06, 2024 | -32.42M |
| June 05, 2024 | -27.44M |
| June 04, 2024 | -30.34M |
| June 03, 2024 | -29.93M |
| May 31, 2024 | -24.95M |
| May 30, 2024 | -28.27M |
| May 29, 2024 | -33.24M |
| May 28, 2024 | -28.69M |
| May 24, 2024 | -29.51M |
| May 23, 2024 | -27.44M |
| May 22, 2024 | -23.30M |
| May 21, 2024 | -27.44M |
| May 20, 2024 | -28.27M |
| May 17, 2024 | -20.81M |
| May 16, 2024 | -17.08M |
| May 15, 2024 | -15.01M |
| May 14, 2024 | -17.91M |
| May 13, 2024 | -20.40M |
| May 10, 2024 | -18.32M |
| Date | Value |
|---|---|
| May 09, 2024 | -15.42M |
| May 08, 2024 | -17.49M |
| May 07, 2024 | -14.59M |
| May 06, 2024 | -16.25M |
| May 03, 2024 | -18.32M |
| May 02, 2024 | -18.32M |
| May 01, 2024 | -15.42M |
| April 30, 2024 | -14.59M |
| April 29, 2024 | -17.50M |
| April 26, 2024 | -23.71M |
| April 25, 2024 | -25.79M |
| April 24, 2024 | -28.69M |
| April 23, 2024 | -22.06M |
| April 22, 2024 | -20.81M |
| April 19, 2024 | -21.23M |
| April 18, 2024 | -24.96M |
| April 17, 2024 | -21.23M |
| April 16, 2024 | -19.57M |
| April 15, 2024 | -18.32M |
| April 12, 2024 | -2.989M |
| April 11, 2024 | 29.34M |
| April 10, 2024 | -26.61M |
| April 09, 2024 | -31.79M |
| April 08, 2024 | -31.03M |
| April 05, 2024 | -32.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-62.64M
Minimum
Feb 05 2024
639.11M
Maximum
Aug 05 2021
114.66M
Average
88.68M
Median
Feb 01 2023
Enterprise Value Benchmarks
| Johnson & Johnson | 357.68B |
| Adial Pharmaceuticals Inc | 0.5205M |
| Eliem Therapeutics Inc | 151.26M |
| Monogram Technologies Inc | 55.16M |
| TG Therapeutics Inc | 2.449B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.03M |
| Total Expenses (Quarterly) | 19.79M |
| EPS Diluted (Quarterly) | -0.47 |
| Earnings Yield | -121.1% |